From Simply Wall Street [18/6/2025]
Neuren Pharmaceuticals (NEU) Stock Overview:
A biopharmaceutical company, develops drugs for the treatment of neurological disorders.
^Rewards:Trading at 31.3% below our estimate of its fair value
^Earnings are forecast to grow 3.28% per year
^Trading at good value compared to peers and industry
^Risk Analysis: No risks detected for NEU from our risk checks
Kens
From Simply Wall Street [18/6/2025]Neuren Pharmaceuticals (NEU)...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.44 |
Change
-0.480(3.72%) |
Mkt cap ! $1.547B | |||
| Open | High | Low | Value | Volume |
| $12.88 | $12.88 | $12.42 | $6.421M | 509.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1411 | $12.42 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.44 | 1692 | 2 |
View Market Depth
| Last trade - 16.10pm 19/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |